These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 9873172)

  • 41. Lipid peroxidation and antioxidant enzyme activities in erythrocytes of type 2 diabetic patients.
    Likidlilid A; Patchanans N; Peerapatdit T; Sriratanasathavorn C
    J Med Assoc Thai; 2010 Jun; 93(6):682-93. PubMed ID: 20572373
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Oxidative stress impairs endothelial nitric oxide levels in Behçets' disease.
    Onur E; Kabaroglu C; Inanir I; Var A; Guvenc Y; Gunay O; Gunduz K
    Cutan Ocul Toxicol; 2011 Sep; 30(3):217-20. PubMed ID: 21345164
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Epidemiological features of Adamantiades-Behçet's disease in Germany and in Europe.
    Zouboulis CC; Kötter I; Djawari D; Kirch W; Kohl PK; Ochsendorf FR; Keitel W; Stadler R; Wollina U; Proksch E; Söhnchen R; Weber H; Gollnick HP; Hölzle E; Fritz K; Licht T; Orfanos CE
    Yonsei Med J; 1997 Dec; 38(6):411-22. PubMed ID: 9509911
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adiponectin levels, insulin resistance and their relationship with serum levels of inflammatory cytokines in patients with Behçet's disease.
    Şahin E; Karaman G; Uslu M; Karul A; Şendur N; Şavk E
    J Eur Acad Dermatol Venereol; 2012 Dec; 26(12):1498-502. PubMed ID: 22035239
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mycophenolate mofetil is ineffective in the treatment of mucocutaneous Adamantiades-Behçet's disease.
    Adler YD; Mansmann U; Zouboulis CC
    Dermatology; 2001; 203(4):322-4. PubMed ID: 11752821
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ocular involvement is associated with HLA-B51 in Adamantiades-Behçet's disease.
    Krause L; Köhler AK; Altenburg A; Papoutsis N; Zouboulis CC; Pleyer U; Stroux A; Foerster MH
    Eye (Lond); 2009 May; 23(5):1182-6. PubMed ID: 18551141
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tumour necrosis factor alpha, lipid peroxidation and NO* are increased and associated with decreased free-radical scavenging enzymes in patients with Weill-Marchesani syndrome.
    Evereklioglu C; Turkoz Y; Calis M; Duygulu F; Karabulut AB
    Mediators Inflamm; 2004 Jun; 13(3):165-70. PubMed ID: 15223607
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Serum interleukin-8 as a serologic marker of activity in Behçet's disease.
    Gür-Toy G; Lenk N; Yalcin B; Aksaray S; Alli N
    Int J Dermatol; 2005 Aug; 44(8):657-60. PubMed ID: 16101867
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of leptin level and Ob gene polymorphism in patients with Behcet's disease.
    Okudan N; Acar H; Gökbel H; Mevlitoğlu I; Sari F
    Arch Dermatol Res; 2006 Aug; 298(3):127-30. PubMed ID: 16786343
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Increased advanced oxidation protein products in Behçet's disease: a new activity marker?
    Yazici C; Köse K; Caliş M; DemIr M; Kirnap M; Ateş F
    Br J Dermatol; 2004 Jul; 151(1):105-11. PubMed ID: 15270878
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Levels of soluble E-selectin in patients with active Behcet's disease.
    Sari RA; Kiziltunç A; Taysi S; Akdemir S; Gündoğdu M
    Clin Rheumatol; 2005 Feb; 24(1):55-9. PubMed ID: 15338451
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adamantiades-Behçet's disease with inner ear involvement.
    Adler YD; Jovanovic S; Jivanjee A; Krause L; Zouboulis CC
    Clin Exp Rheumatol; 2002; 20(4 Suppl 26):S40-2. PubMed ID: 12371634
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tumour necrosis factor-alpha gene promoter region -308 and -376 G-->A polymorphisms in Behçet's disease.
    Duymaz-Tozkir J; Gül A; Uyar FA; Ozbek U; Saruhan-Direskeneli G
    Clin Exp Rheumatol; 2003; 21(4 Suppl 30):S15-8. PubMed ID: 14727453
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Oxidative enzymes of polymorphonuclear leucocytes and plasma fibrinogen, ceruloplasmin, and copper levels in Behçet's disease.
    Doğan P; Tanrikulu G; Soyuer U; Köse K
    Clin Biochem; 1994 Oct; 27(5):413-8. PubMed ID: 7867220
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Familial Behçet's disease.
    Akpolat T; Koç Y; Yeniay I; Akpek G; Güllü I; Kansu E; Kiraz S; Ersoy F; Batman F; Kansu T
    Eur J Med; 1992 Nov; 1(7):391-5. PubMed ID: 1341477
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Auto-oxidative damage in Behçet's disease--endothelial cell damage following the elevated oxygen radicals generated by stimulated neutrophils.
    Niwa Y; Miyake S; Sakane T; Shingu M; Yokoyama M
    Clin Exp Immunol; 1982 Jul; 49(1):247-55. PubMed ID: 7127901
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Serum leptin levels in patients with ocular and nonocular Behçet's disease.
    Yalçindağ FN; Kisa U; Batioğlu F; Yalçindağ A; Ozdemir O; Cağlayan O
    Mediators Inflamm; 2007; 2007():31986. PubMed ID: 17641728
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Urokinase plasminogen activator receptor levels in Behcet's disease.
    Birengel S; Yalçındağ FN; Yalçındağ A; Sahli E; Batıoğlu F
    Thromb Res; 2011 Sep; 128(3):274-6. PubMed ID: 21470667
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Influence of therapy on the antioxidant status in patients with melanoma.
    Gadjeva V; Dimov A; Georgieva N
    J Clin Pharm Ther; 2008 Apr; 33(2):179-85. PubMed ID: 18315784
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Serum interleukin 18 and tumour necrosis factor-alpha levels are increased in Behcet's disease.
    Oztas MO; Onder M; Gurer MA; Bukan N; Sancak B
    Clin Exp Dermatol; 2005 Jan; 30(1):61-3. PubMed ID: 15663506
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.